The Prescription Drug Price Transparency Act, enacted during the 2018 Legislative Session, established Oregon’s Drug Price Transparency program within the Department of Consumer and Business Services. The program is directed by the statute to:
- Increase transparency regarding prescription drug costs and prices from pharmaceutical manufacturers
- Gather information from health insurance companies on prescription drugs
- Provide consumers a way to notify the department on a prescription drug price increase
News and updates
- Annual price increase reporting is open (continue to the reporting system). Reports are due July 1 and are required for prescription drugs with a wholesale acquisition cost of $100 or more and there was a net yearly increase of 10 percent or more in the wholesale acquisition cost.
- Information regarding reports the department has received is posted on the Data page. More data will become available as reports are reviewed and determined complete.
- The Manufacturer User Guide for the general program requirements and new drug reporting is now available.
- New specialty drug reporting began Friday, March 15, 2019. Reports for new drugs with a wholesale acquisition cost of $670 or more are required to be submitted within 30 days of market entry.